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Background: The amount of cell surface GABAB 
receptors determines the strength of GABAB-
mediated inhibition of neuronal excitability. 
Results: GABAB receptors are K48-linked 
polyubiquitinated and degraded by proteasomes 
via ERAD. 
Conclusion: ERAD constitutively degrades 
GABAB receptors and thereby determines the 
number of functional receptors available for 
signaling. 
Significance: Modulation of ERAD activity may 
be a mechanism to adjust the level of functional 
GABAB receptors. 
 
 
SUMMARY 
 Metabotropic GABAB receptors are crucial 
for controlling the excitability of neurons by 
mediating slow inhibition in the CNS. The 
strength of receptor signaling depends on the 
number of cell surface receptors, which is 
thought to be regulated by trafficking and 
degradation mechanisms. While the 
mechanisms of GABAB receptor trafficking are 
studied to some extent, it is currently unclear 
whether receptor degradation actively controls 
the number of GABAB receptors available for 
signaling. Here we tested the hypothesis that 
proteasomal degradation contributes to the 
regulation of GABAB receptor expression levels. 
Blocking proteasomal activity in cultured 
cortical neurons considerably enhanced total 
and cell surface expression of GABAB receptors, 
indicating the constitutive degradation of the 
receptors by proteasomes. Proteasomal 
degradation required K48-linked 
polyubiquitination of lysines 767/771 in the C-
terminal domain of the GABAB2 subunit. 
Inactivation of these ubiquitination sites 
increased receptor levels and GABAB receptor 
signaling in neurons. Proteasomal degradation 
was mediated by endoplasmic reticulum (ER)-
associated degradation (ERAD) as shown by the 
accumulation of receptors in the ER upon 
inhibition of proteasomes, by the increase of 
receptor levels as well as receptor signaling 
upon blocking ERAD function and by the 
interaction of GABAB receptors with the 
essential ERAD components Hrd1 and p97. In 
conclusion, the data support a model in which 
the fraction of GABAB receptor available for 
plasma membrane trafficking is regulated by 
degradation via the ERAD machinery. Thus, 
modulation of ERAD activity by changes in 
physiological conditions may represent a 
mechanism to adjust receptor numbers and 
thereby signaling strength.  
 
 Signaling strength of neurotransmitter receptors 
is significantly controlled by the number of 
receptors in the plasma membrane. Protein 
synthesis, cell surface trafficking, endocytotic 
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removal from the plasma membrane and 
degradation of the receptors need to be precisely 
balanced to maintain an appropriate level of cell 
surface receptors. These mechanisms thus provide 
means for adapting receptor numbers in response 
to plastic changes in neurons. There is 
accumulating evidence that regulated protein 
degradation via the ubiquitin-proteasome system 
plays an important integrative role in synaptic 
plasticity (1-3). Proteasomal degradation at the 
endoplasmic reticulum (ER) is crucial for the 
quality control of newly synthesized receptors. 
Incorrectly folded and misassembled receptor 
proteins are efficiently eliminated from the 
endoplasmic reticulum via the ER-associated 
degradation (ERAD) (4). Defective receptor 
proteins are polyubiquitinated, exported from the 
ER membrane and degraded by proteasomes in the 
cytoplasm. There is evidence that ERAD may also 
be involved in the regulation of the number of 
functional receptors in response to physiological 
stimuli. Prolonged activation of IP3 receptors, 
which release Ca
2+
 from the ER, down-regulates 
the expression of the receptors in ER membranes 
via ERAD-dependent proteasomal degradation (5). 
This is thought to be a homeostatic response to 
counterbalance excessive accumulation of Ca
2+
 in 
the cytoplasm. However, it is currently unclear 
whether the ERAD machinery contributes to the 
regulation of the cell surface density of 
neurotransmitter receptors. 
 GABAB receptors are G protein-coupled 
receptors assembled from the two subunits 
GABAB1 and GABAB2. They mediate slow 
inhibitory neurotransmission in the CNS and are 
thought to be involved in a variety of neurological 
disorders (6). It is meanwhile well established that 
GABAB receptors are endocytosed from the 
plasma membrane via the classical dynamin and 
clathrin-dependent pathway and are eventually 
degraded in lysosomes (7). Lysosomal targeting 
appears to be mediated by the ESCRT (endosomal 
sorting complex required for transport) machinery 
(8) that sorts mono- and K63-linked 
polyubiquitinated proteins to lysosomes (9). It is 
currently unclear whether proteasomal degradation 
contributes to the regulation of GABAB receptors 
available for signal transduction. Therefore, we 
tested in this study the hypothesis that cell surface 
levels of GABAB receptors might be controlled by 
proteasomal degradation. 
 
EXPERIMENTAL PROCEDURES 
 Antibodies  The following primary antibodies 
were used: rabbit GABAB1a,b (10,11) directed 
against the C terminus of GABAB1 (affinity-
purified, 1:500 for in-cell Western assay and 
immunofluorescence), rabbit GABAB2N (10,11) 
directed against the N terminus of GABAB2 
(affinity-purified, 1:250 for in-cell Western assay 
and immunofluorescence, 1:50 for in situ PLA), 
guinea pig GABAB2 (1:1000 for 
immunofluorescence in neurons and 1:4000 in 
HEK 293 cells, 1:1000 for Western blotting, 
Chemicon International), mouse PDI (1:1000 for 
immunofluorescence, Santa Cruz Biotechnology), 
mouse ubiquitin (P4D1, 1:50 for Western blotting, 
Santa Cruz Biotechnology), mouse ubiquitin 
Lys48-specific (clone Apu2, 1:50 for in situ PLA; 
Millipore), mouse VCP (p97) (1:50 for in situ PLA, 
3E8DC11, Abcam), mouse actin (1:1000 for in-cell 
Western assay, Chemicon International), mouse 
HA (1:500 for immunofluorescence, Santa Cruz 
Biotechnology), rabbit SYVN1/Hrd1 (1:50 for in 
situ PLA, Bioss). Secondary antibodies were 
coupled either to horseradish peroxidase (1:5000, 
Jackson ImmunoResearch), Alexa Fluor 488 
(1:1000, Invitrogen), Cy-3 (1:500, Jackson 
ImmunoResearch), IRDye680 (1:400, Li-COR 
Biosciences) or IRDye800CW (1:400, Li-COR 
Biosciences). 
 Drugs – Baclofen (50 M, Tocris Bioscience), 
betulinic acid (20 g/ml, Sigma-Aldrich), 
bicucullin (4 M, Tocris Bioscience), Eeyarestatin 
I (5 M, Chembridge), CNQX (2 M, Tocris 
Bioscience), lactacystin (50 M, Sigma Aldrich), 
MG132 (10 μM, Sigma-Aldrich), pyrenebutyric 
acid (50 M, Sigma-Aldrich), SMI-UPS14 (5 M, 
BostonBiochem), TTX (0.5 M, Tocris 
Bioscience). 
 Plasmids  The following cDNAs in the 
appropriate expression vectors were used: 
GABAB(1a) (12) (pcDNA1), GABAB2 (13) (pcI) 
(pcDNA1, GABAB plasmids were kindly provided 
by Dr. B. Bettler, University of Basle and Dr. K. 
Kaupmann, Novartis, Basle), ubiquitin and 
ubiquitin (K48R) (14) (pRK5-HA, Addgene 
plasmids 17604, 17608), VCP/p97-EGFP and 
VCP/p97(DKO)-EGFP (15) (pEGFP-N1, Addgene 
plasmids 23971, 23974). 
 Mutation of GABAB2  Lysines 767 and 771 in 
GABAB2 were mutated to arginines using the 
Quick change II XL site directed mutagenesis kit 
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from Stratagene according to the manufactors 
instructions. 
 Culture and transfection of cortical neurons  
Primary neuronal cultures of cerebral cortex were 
prepared from E18 embryos of time-pregnant 
Wistar rats as described previously (10,11). 
Neurons were kept in culture for 12 to 17 days 
before used. Neurons were transfected with 
plasmid DNA using magnetofection as detailed by 
Buerli et al. (16). 
 Culture and transfection of HEK 293 cells  
HEK (Human Embryonic Kidney) 293 cells were 
cultured in minimum essential medium (MEM, 
Invitrogen) containing 10% fetal calf serum 
(Invitrogen), 2 mM glutamine (Q, Invitrogen) and 
4% gentamicin (Invitrogen). HEK 293 cells were 
transfected with plasmids using the calcium 
phosphate precipitation method. 
 Proteasome activity assay  Neurons cultured in 
96-well plates were incubated for 12 h with either 
10 M MG132, 50 M lactacystin or 20 M 
betulinic acid followed by determination of 
proteasome activity using the Proteasome Glo 
Chymotrypsin-like cell based assay (Promega) 
according to the manufactures instructions. 
 Immunoprecipitation and Western blotting  
Immunoprecipitation of GABAB receptors from 
deoxycholate extracts of rat brain membranes and 
Western blotting for the detection of GABAB2 and 
ubiquitin was done as described previously (10,17).  
 Immunocytochemistry and confocal laser 
scanning microscopy  Double labeling 
immunocytochemistry was performed with cortical 
neurons cultured on coverslips as described 
previously (10,11,17). Neurons were analyzed by 
confocal laser scanning microscopy (LSM510 
Meta; Zeiss, 100x plan apochromat oil differential 
interference contrast objective, 1.4 NA) at a 
resolution of 1024 x 1024 pixels in the sequential 
mode. Quantification of fluorescence signals and 
image processing was done as detailed in (11). 
Images shown represent a single optical layer. 
 In-cell Western assay  The in-cell Western 
assay was exactly done as in (11). Neurons 
cultured in 96-well plates were treated with the 
drug to be tested for the indicated time at 37 °C 
and 5% CO2. After fixation and permeabilization, 
the neurons were incubated simultaneously with 
GABAB receptor and actin antibodies. Non-
specific GABAB receptor antibody binding was 
determined in parallel cultures by competition 
using the respective peptide-antigen (10 g/ml). 
After incubation with the appropriate secondary 
antibodies the fluorescence was measured with the 
Odyssey Infrared Imaging System (LI-COR 
Biosciences). Specific GABAB signals were 
normalized to the actin signal determined in 
parallel.  
 In situ proximity ligation assay (in situ PLA)  
The in situ PLA technology is a highly sensitive 
antibody-based method for the microscopic 
detection of protein-protein interactions and 
posttranslational protein modifications in cultured 
cells and tissue section (18,19). For in situ PLA we 
used Duolink PLA probes and detection reagents 
according to the manufactures instructions (Olink 
Bioscience). The specificity of the PLA signal was 
validated for each pair of antibodies in HEK 293 
cell expressing or not expressing GABAB receptors. 
In addition, in neurons omitting one of the primary 
antibodies did not generate PLA signals. 
For signal quantification, cells were imaged for 
GABAB receptor expression and PLA signals by 
confocal microscopy (LSM510 Meta; Zeiss, 100x 
plan apochromat oil differential interference 
contrast objective, 1.4 NA, resolution 1024 x 1024 
pixels, sequential mode). GABAB receptor 
fluorescence intensities, PLA spots and the cell 
area were quantified using ImageJ 
(http://rsbweb.nih.gov/ij/). PLA signals were 
normalized to the GABAB receptor signal and the 
cell area. 
 Electrophysiology  Cortical neurons at 13-15 
days in vitro were recorded in the whole-cell 
voltage-clamp configuration at room temperature. 
Total spontaneous postsynaptic currents (sPSCs) 
were recorded at a holding potential of -60 mV. 
Baclofen-evoked potassium currents were elicited 
using a 10 second pulse of 50 M baclofen at -90 
mV. Patch electrodes were filled with 120 mM 
CsCl / KCl, 10 mM EGTA, 10 mM HEPES (pH 
7.4), 4 mM MgCl2, 0.5 mM GTP and 2 mM ATP. 
Spontaneous PSCs recordings were performed 
using intracellular CsCl, whereas the potassium 
currents were recorded using an intracellular 
solution containing KCl. The external solution 
contained 140 mM NaCl, 10 mM KCl, 2 mM 
CaCl2, 1 mM MgCl2, 10 mM HEPES pH 7.4 and 
10 mM glucose. Potassium currents were recorded 
in the presence of TTX (0.5 μM), CNQX (2 μM) 
and bicuculline (4 μM). To enhance the amplitude 
of the baclofen-evoked currents, the potassium 
concentration of the extracellular solution was 
increased to 30 mM and the sodium concentration 
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was reduced to 120 mM (to keep osmolarity 
constant) before the application of the GABAB 
agonist. All the synaptic events displaying 
amplitudes above the background noise (5-12 pA) 
were identified and analyzed off-line using 
MiniAnalysis 6.0.7 software (Synaptosoft). Mean 
amplitudes and frequency values were obtained 
from 1 min epoch’s recordings on each 
experimental condition and normalized to the 
control condition of the individual neuron.  
 Statistical analysis  Data are presented as mean 
± S.E.M.. The statistical analysis of data was 
performed with the GraphPad Prism 5 software. 
Unpaired t-test was used for comparing two 
conditions and one way ANOVA followed by 
Dunnett’s post-hoc test for analysis of multiple 
conditions. The level of significance and n values 
are indicated in the figure legends. Differences 
were considered statistically significant when p< 
0.05. 
 
RESULTS 
 The expression level of GABAB receptors is 
controlled by proteasomal degradation  It is 
currently unknown whether the ubiquitin-
proteasome system contributes to the regulation of 
GABAB receptor expression levels in neurons. To 
gain evidence for a potential degradation of 
GABAB receptors by proteasomes, we treated 
cultured cortical neurons for 12 h with the 
proteasome inhibitors MG132 or lactacystin and 
determined the GABAB1 and GABAB2 protein 
expression levels. Under these conditions, MG132 
and lactacystin decreased proteasomal activity to 
31±2% and 17±1% of untreated controls, 
respectively (Fig. 1A). Both drug treatments 
increased total GABAB receptor expression levels 
(MG132, GABAB1: 131±2 %, GABAB2: 143±5 %; 
lactacystin, GABAB1: 142±4 %, GABAB2: 
147±2 % of control; Fig. 1B), suggesting that 
under basal conditions GABAB receptors were 
constitutively degraded to a certain extent by 
proteasomes. 
 Prolonged inhibition of proteasomes depletes 
the pool of free ubiquitin (20,21), which might also 
affect ubiquitin-dependent processes unrelated to 
proteasomal degradation. There is some evidence 
that GABAB receptors are sorted to lysosomes via 
the ubiquitin-dependent ESCRT (endosomal 
sorting complex required for transport) machinery 
(8). Hence, prolonged inhibition of proteasomes 
might indirectly compromise lysosomal 
degradation of the receptors. However, an indirect 
contribution of lysosomal degradation could be 
ruled out. Pharmacologically increasing 
proteasome activity by treating cortical neurons for 
12 h with the proteasome activator betulinic acid 
(22), which enhanced proteasomal activity to 
143±17% of control (Fig. 1A), significantly 
decreased GABAB receptor levels (GABAB1: 
69±2%, GABAB2: 64±3% of control; Fig. 1C). 
 It has recently been shown that inhibition of the 
proteasome-associated deubiquitinating enzyme 
USP14 enhanced the degradation of proteasome 
substrates (23). Inhibition of USP14 by incubation 
of cortical neurons with SMI-USP14 (small 
molecule inhibitor of USP14) strongly reduced 
GABAB receptor levels (GABAB1: 49±4%, 
GABAB2: 29±2% of control, Fig. 1D), further 
supporting the view that GABAB receptors are 
degraded by proteasomes. 
 Finally, we assessed the functional 
consequences of decreased GABAB receptor levels 
after enhancing proteasomal activity with betulinic 
acid by measuring spontaneous synaptic activity in 
electrophysiological experiments. Activation of 
GABAB receptors with the selective agonist 
baclofen considerably decreased the amplitude as 
well as the frequency of spontaneous postsynaptic 
currents (sPSCs) to 43±4% and 56±7%, 
respectively (Fig. 1E). Treatment of cultures for 12 
h with betulinic acid diminished baclofen-induced 
inhibition of sPSCs (amplitude: from 43±4% to 
90±12% of control, frequency: from 56±7% to 
94±15% of control; Fig. 1E), supporting the 
hypothesis that enhanced proteasomal activity 
leads to reduced levels of functional GABAB 
receptors available for neuronal inhibition. 
 
 GABAB receptors undergo K48-linked 
polyubiquitination  K48-linked 
polyubiquitination of proteins serves as a signal for 
proteasomal degradation. Consistent with poly-
ubiquitination, GABAB receptors 
immunoprecipitated from deoxycholate extracts of 
crude rat brain membranes exhibited on Western 
blots ubiquitin immunoreactivity in the high 
molecular range (Fig. 2A). This suggests that 
GABAB receptors are ubiquitinated under basal 
conditions to a certain extent. Likewise, using the 
in situ proximity ligation assay (PLA), we found 
that GABAB receptors in cultured cortical neurons 
display K48-linked polyubiquitination, which was 
considerably increased upon inhibition of 
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proteasomal activity with MG 132 (172±11% of 
control, Fig. 2B). This indicates the accumulation 
of K48-linked polyubiquitinated GABAB receptors 
destined for proteasomal degradation. 
 Next we tested whether preventing K48-linked 
polyubiquitination affects GABAB receptor levels. 
Over-expression in neurons of a K48-chain 
elongation-defective ubiquitin mutant, in which 
lysine (K) 48 had been exchanged for an arginine 
(R) (Ub(K48R)), considerably increased the level 
of GABAB receptors (GABAB1: 166±7%, 
GABAB2: 140±7% of control, Fig. 2C). This 
finding corroborates a K48-linked polyubiquitin-
mediated proteasomal degradation of GABAB 
receptors. 
 
 The C-terminal domain of GABAB2 contains a 
major K48-linked polyubiquitination site  An in 
silico analysis predicted two lysines in the C-
terminal domain of GABAB2 at position 767 and 
771 as likely candidates for ubiquitination. We 
inactivated these potential ubiquitination sites by 
exchanging both lysines for arginines 
(GABAB2(RR)) (Fig. 3A). Upon transfection into 
HEK 293 cells, GABAB2(RR) displayed reduced 
K48-linked polyubiquitination (61±6% of wild 
type; Fig. 3B), indicating that K767/771 is a main 
site for K48-linked polyubiquitination in GABAB2. 
 We then tested whether GABAB1 is also a target 
for K48-linked polyubiquitination. However, HEK 
293 cells transfected with GABAB1 showed only 
marginal GABAB1/K48-linked ubiquitination PLA 
signals as compared to HEK 293 cells expressing 
GABAB1 and GABAB2 (12±6%, Fig. 3C). In line 
with this finding, coexpression of GABAB1 with 
GABAB2(RR) yielded a similar reduction in 
GABAB receptor/K48-linked polyubiquitination 
signals (56±8%, Fig. 3C) as observed for 
GABAB2(RR) alone (61±6%, Fig. 3B). Thus, 
GABAB2 appears to be the main target for K48-
linked polyubiquitination of GABAB receptors. 
 Over-expressing GABAB2(RR) in cultured 
neurons increased GABAB receptor levels to a 
similar level as observed after chronic proteasome 
inhibition (GABAB1: 152±15%, GABAB2: 146±9% 
of control; Fig. 3D). This suggests that K767/771 
in GABAB2 is the major K48-linked 
polyubiquitination site required for proteasomal 
degradation of GABAB receptors. 
 The functional consequence of the increased 
GABAB2 cell surface density after transfecting 
neurons with GABAB2(RR) was analyzed by 
measuring baclofen-induced K
+
 currents using 
whole-cell patch-clamp recordings. Transfection of 
GABAB2(RR) in neurons resulted in 2.8±0.6-fold 
increased K
+
 channel current amplitudes after 
activation of GABAB receptors with baclofen as 
compared to neurons transfected with wild type 
GABAB2 (Fig. 3E). Thus, preventing proteasomal 
degradation of GABAB2 by over-expression of 
GABAB2(RR) increased the number of functional 
cell surface GABAB receptors available for 
signaling. 
 
 Cell surface expression of GABAB receptors is 
regulated by ERAD  The most likely mechanism 
for proteasomal degradation of GABAB receptors 
is the ER-associated degradation (ERAD). If 
GABAB receptors are degraded by ERAD, 
inhibition of proteasomal activity should result in 
an accumulation of GABAB receptors in the ER. 
Indeed, blocking porteasomal activity in neurons 
for 12 h with MG132 increased the number of 
GABAB2 clusters (136±6% of control) as well as 
the clusters co-localizing with a marker protein for 
the ER (protein disulfide isomerase [PDI], 133±7% 
of control, Fig. 4A). 
 To further establish the role of ERAD in 
regulating cellular GABAB receptor levels we 
tested the effect of directly inhibiting ERAD. 
Treatment of neurons for 12 h with the ERAD 
inhibitor Eeyarestatin I (EerI) (24,25) increased 
both total GABAB2 (183±15% of control, Fig. 4B) 
and cell surface levels of GABAB2 (204±32% of 
control, Fig. 4C). Over-expression of 
GABAB2(RR), which lack the main K48-linked 
polyubiquitination sites, did not further increase 
total (112±7% of control, Fig. 4D) or cell surface 
GABAB receptor levels (93±15% of control, Fig. 
4E). These observations indicate that K48-linked 
polyubiquitinated GABAB receptors are degraded 
by ERAD. 
 
 GABAB receptors interact with the ERAD E3 
ubiquitin ligase Hrd1 – Hrd1 is one prototypical 
ERAD E3 ubiquitin ligases responsible for K48-
linked polyubiquitination of ERAD substrates (26). 
Using in situ PLA, we further confirmed the 
potential degradation of GABAB receptors via 
ERAD by showing that GABAB receptors interact 
with Hrd1 (Fig. 5A). Inhibition of ERAD for 12 h 
with EerI increased the number of interactions 
(GABAB2/Hrd1: 490±45%, GABAB1/Hrd1: 
305±18% of control; Fig. 5A), indicating the 
 at H
auptbibliothek U
niversitaet Zuerich Irchel. Bereich Forschung on M
arch 10, 2014
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
ERAD controls GABAB receptor cell surface expression 
 
6 
accumulation of GABAB receptors at this central 
ERAD multiprotein complex. In line with this 
observation, blocking ERAD function for 12 h 
with EerI considerably increased the level of K48-
linked polyubiquitinated GABAB receptors 
(242±21% of control, Fig. 5B). 
 
 GABAB receptors interact with the essential 
ERAD component p97  The AAA-ATPase p97 is 
a central constituent of the ERAD machinery 
involved in the retrotranslocation of proteins to the 
cytoplasm for proteasomal degradation (27). Using 
in situ PLA, we found that GABAB receptors 
interact with p97 (Fig. 6A). This finding further 
demonstrates the ERAD-mediated degradation of 
GABAB receptors. Inhibition of p97 by EerI 
decreased the interaction of GABAB2 with p97 
(40±8% of control; Fig. 6A), suggesting that the 
association is activity-dependent. 
 Inhibition of p97 function in neurons by over-
expression of a dominant-negative mutant of p97 
(p97[DKO]) considerably increased total 
(176±11% of control, Fig. 6B) as well as cell 
surface GABAB receptor levels (143±11% of 
control; Fig. 6C) as compared to neurons over-
expressing wild type p97. Over-expressing in 
addition GABAB2(RR) did not further increase 
total (wild type p97: 100±6%, p97(DKO): 104±6%, 
Fig. 6D) or cell surface GABAB receptor levels 
(wild type p97: 100±12%, p97(DKO): 100±11%, 
Fig. 6E), indicating that ubiquitination of GABAB2 
is required for being recognized by the ERAD 
machinery. 
 Whole-cell patch-clamp recordings finally 
verified that inhibition of ERAD function by over-
expression of p97(DKO) increased the level of 
functional cell surface GABAB receptors (Fig. 6F). 
Neurons over-expressing p97(DKO) displayed 
considerably increased amplitudes of baclofen-
induced K
+
 currents (control: 72±14 pA, 
p97(DKO): 139±14 pA; Fig. 7 F). These 
experiments show that GABAB receptors are 
degraded by ERAD, which affects the levels of 
total and cell surface GABAB receptors. 
 
DISCUSSION 
 Mechanisms controlling the cell surface density 
of GABAB receptors are of pivotal importance for 
determining the level of GABAB receptor-mediated 
neuronal inhibition. Because GABAB receptors 
control glutamatergic neurotransmission (28) 
modulation of their cell surface density is 
presumed to significantly contribute to synaptic 
plasticity. However, the mechanisms that control 
cell surface expression of GABAB receptors are 
largely unknown. In the present study, we 
identified proteosomal degradation via the ER-
resident ERAD machinery as a mechanism that 
determines cell surface expression of GABAB 
receptors.  
 Our data indicate that a fraction of GABAB 
receptors in the ER is constitutively K48-linked 
polyubiqutinated and degraded by the ERAD 
machinery. This conclusion is based on the 
observation that blocking proteasomal activity, 
inhibiting ERAD function or interfering with 
GABAB receptor K48-linked polyubiquitination 
increased the expression levels of GABAB 
receptors in neurons. Lysines 767/771 in the C-
terminal domain of GABAB2 appear to represent 
the main K48-linked polyubiquitination sites 
required for proteasomal degradation as their 
mutational inactivation rendered GABAB receptors 
largely immune to degradation. It is currently 
unclear whether K48-linked polyubiquitination of 
both lysines or only of K767 or K771 serves as a 
tag for proteasomal degradation. A recent 
proteomic study analyzing the ubiquitination state 
of rat brain synaptic proteins identified K771 in 
GABAB2 as being ubiquitinated (29). This 
observation favors K771 as the main K48-linked 
polyubiquitination site in GABAB2. 
There are several lines of evidence that in 
particular GABAB receptors residing in the ER are 
degraded by proteasomes via ERAD. First, upon 
blocking proteasomal activity the receptors 
accumulated in the ER. Second, blocking ERAD 
function pharmacologically or by over-expressing 
a dominant-negative mutant of the AAA-ATPase 
p97, which mediates the retrotranslocation of 
proteins to the cytoplasm for proteasomal 
degradation (27), increased GABAB receptor levels. 
Third, GABAB receptors interacted with the ERAD 
proteins p97 and Hrd1. Hrd1 is the prototypical 
ERAD E3 ligase (26) and most likely one of the 
ubiquitin ligases that mediate ubiquitination of 
GABAB receptors because stalling proteasomal 
degradation considerably increased its interaction 
with GABAB receptors and the level of K48-linked 
polyubiquitinated GABAB receptors.  
 In all cases tested, GABAB1 and GABAB2 were 
concomitantly up- or down-regulated to a similar 
extent, suggesting that assembled GABAB receptor 
complexes are degraded by ERAD. This notion is 
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further strengthened by the finding that 1) 
inactivation of the ubiquitination sites in GABAB2 
increased the expression levels of GABAB1 and 
GABAB2 as well as GABAB receptor-activated K
+
 
current amplitudes, 2) that interfering with ERAD 
function increased GABAB receptor function 
(baclofen-induced K
+
 currents) and 3) that both 
GABAB1 and GABAB2 generated in situ PLA 
signals with the ERAD E3 ubiquitin ligase Hrd1 
although only K48-linked polyubiquitination of 
K767/771 in GABAB2 appears to be required for 
proteasomal degradation of the receptors.  
What might be the physiological implications of 
this mechanism? The most firmly established 
function of ERAD is the degradation aberrant 
proteins in the ER (30). In addition, ERAD has 
been shown to rapidly degrade activated IP3 
receptors in the ER to prevent excessive elevation 
of cytosolic Ca
2+
 concentrations (5), indicating that 
ERAD may also contribute to the regulation of 
functional receptors. Because blocking ERAD 
increased the level of functional GABAB receptors 
and ERAD appears to degrade assembled 
heterodimeric receptors it is rather unlikely that the 
role of ERAD is simply the degradation of un- or 
misfolded GABAB receptor subunits. The 
constitutive degradation of GABAB receptors 
suggests that ERAD controls the amount of 
receptors available for cell surface trafficking. This 
view is supported by recent studies on the 
regulation of cell surface GABAA receptors. 
Chronic suppression of neuronal activity or 
inhibition of L-type voltage-gated calcium 
channels decreased the level of functional GABAA 
receptors in the neuronal plasma membrane by a 
mechanism dependent on the ubiquitination of the 
GABAA receptor -subunit and proteasome 
activity, most likely via the ERAD pathway 
(31,32). These findings imply that regulation of 
ERAD activity is a potential mechanism to adjust 
the level of functional GABAB receptors to 
changing physiological condition. Our finding that 
modulation of proteasomal activity up- or down-
regulates the level of functional GABAB receptors 
supports this view. Interestingly, the level of 
proteasomal activity correlates with the activity 
state of neurons (33). We therefore hypothesize 
that the amount of functional GABAB receptors 
inserted into the plasma membrane is regulated by 
neuronal activity via ERAD.  
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FIGURE LEGENDS 
 
FIGURE 1. The expression level of GABAB receptors is controlled by proteasomes.  
A, Verification of drug effects on proteasome activity. Neurons were incubated for 12 h with the indicated 
drugs and tested for proteasome activity. n=12 cultures; **, p<0.01, ANOVA. 
B, Blocking proteasome activity increased the level of GABAB receptors. Neurons were incubated for 12 h 
with drugs and GABAB receptor levels were determined using the in-cell Western assay. Untreated 
neurons served as a control. n=40 cultures, **, p<0.01; ***, p<0.001, ANOVA. 
C, Enhancing proteasome activity decreased the level of GABAB receptors. Neurons were incubated for 
12 h with betulinic acid, followed by determination of GABAB receptor levels using the in-cell Western 
assay. n=40 cultures, ***, p<0.0001, t-test. 
D, Inhibition of the deubiquitinating enzyme USP14 decreased the expression level of GABAB receptors. 
Neurons were incubated for 12 h with SMI-USP14 (USP14) and tested for GABAB1 and GABAB2 levels 
using the in-cell Western assay. n=20-27 cultures, ***, p<0.0001, t-test. 
E, Enhancing proteasome activity diminished baclofen-induced inhibition of spontaneous postsynaptic 
currents (sPSCs). Left: Representative current traces showing sPSCs recorded from untreated cultured 
cortical neurons or from neurons treated for 12 h with betulinic acid. Right: Normalized amplitude and 
frequency values of the sPSCs. Mean amplitudes and frequency values were normalized to the control 
condition of the individual neuron. Con.: control, bac.: baclofen, betu.: betulinic acid. n=6, *, p < 0.05, t-
test. 
 
FIGURE 2. K48-linked ubiquitination controls the expression level of GABAB receptors. 
A, Demonstration of ubiquitination of native GABAB receptors. GABAB receptors were 
immunoprecipitated from deoxycholate extracts of rat brain membranes using either GABAB1a,b or 
GABAB2N antibodies. The immunoprecipitate was subjected to Western blotting for detection of GABAB2 
 at H
auptbibliothek U
niversitaet Zuerich Irchel. Bereich Forschung on M
arch 10, 2014
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
ERAD controls GABAB receptor cell surface expression 
 
10 
and ubiquitin. The high molecular smear detected with the ubiquitin antibody is typical for 
polyubiquitinated proteins. The ubiquitin signal in the GABAB1 immunoprecipitate was considerably 
weaker than in the GABAB2 immunoprecipitate because the GABAB1a,b antibody beads were less efficient 
in precipitating GABAB receptors than the GABAB2 antibody beads. Specificity of the 
immunoprecipitation was verified with non-immune antibodies (control). IP, immunoprecipitate; Ab, 
antibody. 
B, Inhibition of proteasomes enhanced K48-linked polyubiquitination of GABAB receptors. Neurons were 
incubated for 12 h in the absence (control) or presence of MG132 and processed for in situ PLA using 
antibodies directed against GABAB2 and K48-linked polyubiquitin to detect K48-linked polyubiquitinated 
GABAB receptors (white dots in images, left). Right: Quantification of in situ PLA signals. n=30 neurons, 
***, p<0.0001; t-test. Scale bar: 5 μm. 
C, Over-expression in neurons of a K48-chain elongation defective ubiquitin mutant up-regulated GABAB 
receptors. Neurons were transfected with plasmids containing HA-tagged ubiquitin (Ub) or HA-tagged 
mutant ubiquitin (Ub(K48R)). Neurons were stained for GABAB1 or GABAB2 (red) and Ub (green). Top: 
representative images. Bottom: quantification of total GABAB1 and GABAB2 levels in neurons expressing 
Ub or Ub(K48R). n=28-40 neurons, ***, P<0.0001; t-test. Scale bar: 10 μm. 
 
FIGURE 3. The C-terminal domain of GABAB2 contains a major K48-linked ubiquitination site. 
A, Scheme depicting the location of mutated lysines in GABAB2. 
B, Decreased K48-linked polyubiquitination of a GABAB2 mutant in which lysines 767 and 771 had been 
changed to arginines (GABAB2(RR)). HEK293 cells were transfected with plasmids containing either 
GABAB2 or GABAB2(RR) together with HA-Ub plasmid. Cells were analyzed by in situ PLA using 
antibodies directed against GABAB2 and K48-linked polyubiquitin to detect K48-linked polyubiquitinated 
GABAB2 (left, white dots, scale bar: 5 μm). Right: quantification of PLA signals. n=30 cells, ***, 
p<0.0001, t-test. 
C, GABAB2 is the main target for K48-linked polyubiquitination. HEK 293 cells were transfected with 
plasmids containing cDNA for ubiquitin and either GABAB1 alone, GABAB1 and wild type GABAB2 or 
GABAB1 and GABAB2(RR). Cells were analyzed by in situ PLA to detect K48-linked polyubiquitinated 
GABAB receptors (left, white dots, scale bar: 5 μm). Right: quantification of PLA signals. n=25-30 cells, 
**, p<0.001, ***, p<0.0001, ANOVA. 
D, Increased GABAB receptor expression levels in neurons over-expressing GABAB2(RR). Neurons were 
co-transfected with plasmids containing GFP and GABAB2 or GFP and GABAB2(RR) and stained for 
GABAB2 (left, upper panels) or GABAB1 (left, lower panels). Right: quantification of fluorescence signals. 
n=27 (GABAB1) and 40 (GABAB2) neurons, ***, p=0.0003; t-test. Scale bar: 10 μm. 
E, Over-expression of GABAB2(RR) in neurons increased GABAB receptor-mediated K
+
 currents. Left: 
Representative traces of baclofen-induced K
+
 currents recorded in neurons transfected with wild type 
GABAB2 or GABAB2(RR). Right: Normalized K
+
 current amplitudes. Current amplitude of GABAB2(RR) 
transfected neurons were normalized to the mean of current amplitudes recorded from GABAB2 
transfected neurons. bac.: baclofen. n=16 for GABAB2 and n=18 for GABAB2(RR), *, p < 0.05, t-test. 
 
FIGURE 4. GABAB receptors are degraded via the ERAD pathway.  
A, Blocking proteasomal activity increased the number of GABAB2 clusters co-localized with the ER 
marker protein PDI. Neurons were incubated for 12 h with MG132 and stained for GABAB2 (red) and PDI 
(green). The yellow clusters in the merged image indicate the co-localization of GABAB2 and PDI (scale 
bars: 5 μm, 1 m for insets). Lower panels: quantification revealed enhanced co-localization of GABAB2 
and PDI after proteasome inhibition. Control refers to the number of clusters in neurons not treated with 
MG132. n=25-30 neurons, ***, p<0.0001; t-test.  
B-E, Blocking the ERAD pathway increased the level of GABAB receptors. Neurons were transfected with 
plasmids containing EGFP (for detection of transfected neurons) and either wild type GABAB2 (B, C) or 
GABAB2(RR) (D, E). After 48 h cultures were incubated for 12 h with or without (controls) the ERAD 
blocker Eeyarestatin I (EerI). Total (B, D) and cell surface (C, E) GABAB receptor levels were determined 
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immunocytochemically using GABAB2 antibodies (red, upper panels). Scale bars: 10 μm. Lower panels: 
quantification of GABAB2 fluorescence signals. n=28-30 neurons; ***, p<0.0001, n.s., p>0.05; t-test.  
 
FIGURE 5. GABAB receptors interact with the ERAD E3 ligase Hrd1. 
A, Demonstration of the interaction of GABAB receptors with the ERAD E3 ligase Hrd1 using in situ PLA 
with Hrd1 and GABAB2 antibodies (left, upper panels) or GABAB1 antibodies in cortical neurons (left, 
lower panels). Treatment of neurons for 12 h with EerI strongly increased the number of interactions. 
Right: quantification of in situ PLA signals. n=21-27 neurons, ***, p<0.0001; t-test. Scale bar: 5 m. 
B, Inhibition of ERAD induced the accumulation of K48-linked polyubiquitinated GABAB receptors. 
Neurons were incubated with EerI for 12 h and analyzed for K48-linked ubiquitination using in situ PLA 
(white dots in representative images, scale bar: 5 μm). Right: quantification of in situ PLA signals. n=32 
cells, ***, p<0.0001, t-test. 
 
FIGURE 6. GABAB receptors interact with the ERAD AAA-ATPase p97. 
A, Demonstration of the interaction of GABAB receptors with the ERAD AAA-ATPase p97 in cortical 
neurons using in situ PLA. Treatment of neurons for 12 h with the p97 inhibitor EerI strongly reduced the 
interaction. Left: quantification of in situ PLA signals. n=18-21 neurons, ***, p<0.0001; t-test. Scale bar: 
5 m. 
B-C, Disruption of ERAD function by over-expression of a dominant-negative mutant of p97 enhanced 
the level of total (B) and cell surface GABAB2 receptors (C). Neurons were transfected with plasmids 
containing HA-tagged p97 or its dominant-negative mutant HA-tagged p97(DKO) and stained for 
GABAB2 (red) and HA (green). Scale bars: 10 μm. Lower panels: quantification of GABAB2 fluorescence 
signals. n=40-50 neurons, ***, p<0.0001; t-test. 
D-E, Over-expression of GABAB2(RR) in neurons transfected with wild type p97 or p97(DKO) did not 
result in an additional increase of total (D) or cell surface (E) GABAB2 levels. Neurons were transfected 
with plasmids containing GABAB2(RR) and either HA-tagged p97 or its dominant-negative mutant HA-
tagged p97(DKO) and stained for GABAB2 (red) and HA (green). Scale bars: 10 μm. Lower panels: 
quantification of GABAB2 fluorescence signals. n=28-30 neurons; n.s., p>0.05; t-test.  
F, Disruption of ERAD by over-expression of p97(DKO) in neurons increased GABAB receptor-mediated 
K
+
 currents. Neurons were transfected either with plasmids containing EGFP (control) or with plasmids 
containing p97(DKO). Left: Representative traces of baclofen-induced K
+
 currents. Right: K
+
 current 
amplitudes. n=10 for control and n=8 for p97(DKO), *, p < 0.05, t-test. 
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Fig. 6
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